Harmony Biosciences Stock - Analyst consensus and technical backdrop
20.06.2026 - 20:27:30 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 20:25 CET. Details in the imprint.
Harmony Biosciences (US41319J1088) carries a Hold consensus from Wall Street analysts while its shares trade in a narrow band on Nasdaq. Analyst data compiled over the past 12 months and recent technical readings outline a cautiously balanced setup for the stock.
All news and analysis on Harmony Biosciences stock
Key figures, price data and regulatory disclosures help frame the risk-reward profile of Harmony Biosciences for equity investors.
What recent analyst data show
According to MarketBeat, Harmony Biosciences holds a consensus rating of Hold based on 11 analyst opinions collected over the last 12 months, with 4 Buys, 6 Holds and 1 Sell in the distribution. MarketBeat summarizes the rating breakdown and targets.
The same compilation lists a recent closing price of $33.28 on 06/18/2026 in regular trading, with a small uptick to $33.30 in the extended session that day. The data reflect Nasdaq quote information.
Saturday focus on long-term positioning
With no fresh company-specific filings or ad-hoc news in the last 24 hours, the Saturday lens for Harmony Biosciences turns to how the market prices its long-term business model in sleep and neurological disorders.
A Hold consensus often signals that analysts see the current valuation roughly aligned with their risk-adjusted view of earnings power, even where individual price targets imply upside or downside from spot levels.
How the technical picture looks
On the chart side, third-party technical analysis sites place Harmony Biosciences shares around $33.28, down 1.45% at the close on 06/18/2026, with the stock trading between a support zone near $30.18 and resistance around $36.17. TradingKey lists these levels and momentum scores.
That range suggests a market still testing the balance between growth expectations from the pipeline and competitive, regulatory and reimbursement risks in the sleep-disorder segment.
The long-term business model
Harmony Biosciences generates most of its revenue from therapies for rare sleep disorders, anchored by its narcolepsy treatment WAKIX (pitolisant), which is approved in the United States for excessive daytime sleepiness in adult narcolepsy patients and has been expanded into cataplexy.
The company continues to invest in clinical development to broaden pitolisant’s label and explore additional indications in neurological and sleep-related conditions, aiming to extend the product lifecycle and diversify revenue.
The product behind the stock
The key commercial product WAKIX is a first-in-class, orally administered selective histamine 3 receptor antagonist/inverse agonist that promotes wakefulness through histaminergic activation in the brain, differentiating it from stimulant-based narcolepsy treatments.
Where the stock trades today
The shares of Harmony Biosciences (US41319J1088) last closed on Nasdaq at $33.28 on 06/18/2026, 16:00 ET, according to recent quote data.
Harmony Biosciences at a glance
- Company: Harmony Biosciences Holdings Inc.
- ISIN: US41319J1088
- Ticker: HRMY
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 33.28 USD
- Sector / Industry: Health Care / Biotechnology
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
